Madrid Authorizes Phase 3 COVID-19 Vaccine Study

The Spanish Agency for Medicines and Health Products authorized a phase III of the clinical trial in Spain of the Janssen (a Johnson & Johnson company) Ad26.COV2-S vaccine candidate. This is the first phase III clinical trial for a vaccine against COVID-19 of this type authorized in Spain. 

This coronavirus vaccine study will be conducted in 9 hospitals in Spain that will begin to recruit eligible volunteers, which include both people without any chronic diseases and people with concurrent illnesses.

Known as Ad26.COV2.S, this vaccine is based on a soundly documented technology with a non-replicative recombinant adenovirus, to generate an immunological response to one of the coronavirus proteins known as protein S (from spike, proteína espiga in Spanish).